Vivos Therapeutics prices $8M private placement at $1.20/unit with warrants

Vivos Therapeutics, Inc.

Gross proceeds of $8.0M from private placement; net proceeds ~$7.5M after fees.
Price of $1.20 per unit (one share or pre-funded warrant plus one warrant exercisable at $1.20 for 5.5 years).
Company to issue 2M shares, pre-funded warrants for ~4.67M shares, and warrants for 6.67M shares.
Proceeds used for general working capital and corporate purposes.
Registration rights agreement to be filed within 30 days; penalties up to 10.5% of gross proceeds if not effective.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Vivos Therapeutics, Inc. entered into Registration Rights Agreement with institutional investor valued at file a registration statement with the SEC to register for resale the Shares and the shares of Commo (effective 2023-01-05).

Action: entry
Agreement: equity purchase
Counterparty: institutional investor
Value: file a registration statement with the SEC to register for resale the Shares and the shares of Commo
Effective: 2023-01-05

Exact text from the filing

On January 5, 2023, in connection with the Private Placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the Purchaser, pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission (the “SEC”) to register for resale the Shares and the shares of Common Stock issuable upon exercise of the Warrants within 30 days of the signing of the Registration Rights Agreement, with such registration statement to be effective by February 14, 2023 (if such registration statement is not subject to review by the SEC) or within 75 days after the signing of the Registration Rights Agreement (if such registration statement is subject to limited or full review by the SEC).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Vivos Therapeutics, Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC and A.G.P./Alliance Global Partners valued at cash fee equal to 6.0% of the gross proceeds received by the Company in the Private Placement, in ad (effective 2023-01-05).

Action: entry
Agreement: underwriting
Counterparty: Roth Capital Partners, LLC and A.G.P./Alliance Global Partners
Value: cash fee equal to 6.0% of the gross proceeds received by the Company in the Private Placement, in ad
Effective: 2023-01-05

Exact text from the filing

Pursuant to a placement agency agreement, dated January 5, 2023, between the Company and the Placement Agents (the “Placement Agency Agreement”), the Company agreed to pay the Placement Agent a cash fee equal to 6.0% of the gross proceeds received by the Company in the Private Placement, in addition to the reimbursement of $40,000 of expenses.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Vivos Therapeutics, Inc. entered into Securities Purchase Agreement with institutional investor valued at up to an aggregate of $8,000,000 of securities (effective 2023-01-05).

Action: entry
Agreement: equity purchase
Counterparty: institutional investor
Value: up to an aggregate of $8,000,000 of securities
Effective: 2023-01-05

Exact text from the filing

On January 5, 2023, Vivos Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (“Purchase Agreement”) with an institutional investor (the “Purchaser”) pursuant to which the Company agreed sell up to an aggregate of $8,000,000 of securities of the Company in a private placement (the “Private Placement”) of units.

View on SEC.gov

Browse all material agreements →

Vivos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-000896

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.